Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 7/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.51 |
| ▸ | ADH1A | P07327 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ABL2 | P42684 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13596672 | 1.00 | PDGFRB (0.51) | PDGFRBPDGFRAADH1AKITFLT1 | |
| SCHEMBL6390745 | 0.92 | PDGFRB (0.47) | PDGFRBPDGFRAADH1AKITFLT1 | |
| SCHEMBL8113421 | 0.92 | PDGFRB (0.51) | PDGFRBPDGFRAADH1AKITFLT1 | |
| SCHEMBL6521167 | 0.91 | ADH1A (0.50) | PDGFRBPDGFRAADH1AKITFLT1 | |
| SCHEMBL6518434 | 0.91 | ADH1A (0.52) | PDGFRBPDGFRAADH1AKITFLT1 | |
| SCHEMBL6518437 | 0.91 | ADH1A (0.52) | PDGFRBPDGFRAADH1AKITFLT1 | |
| SCHEMBL6521161 | 0.91 | ADH1A (0.50) | PDGFRBPDGFRAADH1AKITFLT1 | |
| SCHEMBL12795535 | 0.90 | PDGFRB (0.46) | PDGFRBPDGFRAADH1AKITFLT1 | |
| SCHEMBL19266907 | 0.90 | PDGFRB (0.46) | PDGFRBPDGFRAADH1AKITFLT1 | |
| SCHEMBL24455433 | 0.90 | PDGFRB (0.49) | PDGFRBPDGFRAADH1AKITFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2022109335-A1 | GLYCOSIDE DUAL-CLEAVAGE LINKERS FOR ANTIBODY-DRUG CONJUGATES | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20210369705-A1 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS | MERCK PATENT GMBH (DE) | 2021-12-02 | — | — | US | disclosed |
| WO-2020154437-A1 | GLYCOSIDE-CONTAINING PEPTIDE LINKERS FOR ANTIBODY-DRUG CONJUGATES | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200087297-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20200087297-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-10556895-B2 | Quaternary amine compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| WO-2018031448-A1 | NEAR-IR LIGHT-CLEAVABLE CONJUGATES AND CONJUGATE PRECURSORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-02-15 | — | — | WO | disclosed |
| EP-3226909-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | Genentech, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170232113-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017027721-A1 | NEAR-IR LIGHT-CLEAVABLE CONJUGATES AND CONJUGATE PRECURSORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016090050-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090050-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369705-A1 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS | ATR, TOP2A, TOP1 | PDGFRB 1063/4885PDGFRA 898/4885ADH1A 3241/4885 |
| US-20170232113-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | H1-5, H1-4, CD47 | PDGFRB 1287/4885PDGFRA 1209/4885ADH1A 1665/4885 |
| US-10556895-B2 | Quaternary amine compounds and antibody-drug conjugates thereof | H1-5, H1-4, CD47 | PDGFRB 1287/4885PDGFRA 1209/4885ADH1A 1665/4885 |
| US-20200087297-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | H1-5, H1-4, CD47 | PDGFRB 1287/4885PDGFRA 1209/4885ADH1A 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.